Cargando…
Targeting the IDO1 pathway in cancer: from bench to bedside
Indoleamine 2, 3-dioxygenases (IDO1 and IDO2) and tryptophan 2, 3-dioxygenase (TDO) are tryptophan catabolic enzymes that catalyze the conversion of tryptophan into kynurenine. The depletion of tryptophan and the increase in kynurenine exert important immunosuppressive functions by activating T regu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090955/ https://www.ncbi.nlm.nih.gov/pubmed/30068361 http://dx.doi.org/10.1186/s13045-018-0644-y |
_version_ | 1783347297931755520 |
---|---|
author | Liu, Ming Wang, Xu Wang, Lei Ma, Xiaodong Gong, Zhaojian Zhang, Shanshan Li, Yong |
author_facet | Liu, Ming Wang, Xu Wang, Lei Ma, Xiaodong Gong, Zhaojian Zhang, Shanshan Li, Yong |
author_sort | Liu, Ming |
collection | PubMed |
description | Indoleamine 2, 3-dioxygenases (IDO1 and IDO2) and tryptophan 2, 3-dioxygenase (TDO) are tryptophan catabolic enzymes that catalyze the conversion of tryptophan into kynurenine. The depletion of tryptophan and the increase in kynurenine exert important immunosuppressive functions by activating T regulatory cells and myeloid-derived suppressor cells, suppressing the functions of effector T and natural killer cells, and promoting neovascularization of solid tumors. Targeting IDO1 represents a therapeutic opportunity in cancer immunotherapy beyond checkpoint blockade or adoptive transfer of chimeric antigen receptor T cells. In this review, we discuss the function of the IDO1 pathway in tumor progression and immune surveillance. We highlight recent preclinical and clinical progress in targeting the IDO1 pathway in cancer therapeutics, including peptide vaccines, expression inhibitors, enzymatic inhibitors, and effector inhibitors. |
format | Online Article Text |
id | pubmed-6090955 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60909552018-08-17 Targeting the IDO1 pathway in cancer: from bench to bedside Liu, Ming Wang, Xu Wang, Lei Ma, Xiaodong Gong, Zhaojian Zhang, Shanshan Li, Yong J Hematol Oncol Review Indoleamine 2, 3-dioxygenases (IDO1 and IDO2) and tryptophan 2, 3-dioxygenase (TDO) are tryptophan catabolic enzymes that catalyze the conversion of tryptophan into kynurenine. The depletion of tryptophan and the increase in kynurenine exert important immunosuppressive functions by activating T regulatory cells and myeloid-derived suppressor cells, suppressing the functions of effector T and natural killer cells, and promoting neovascularization of solid tumors. Targeting IDO1 represents a therapeutic opportunity in cancer immunotherapy beyond checkpoint blockade or adoptive transfer of chimeric antigen receptor T cells. In this review, we discuss the function of the IDO1 pathway in tumor progression and immune surveillance. We highlight recent preclinical and clinical progress in targeting the IDO1 pathway in cancer therapeutics, including peptide vaccines, expression inhibitors, enzymatic inhibitors, and effector inhibitors. BioMed Central 2018-08-02 /pmc/articles/PMC6090955/ /pubmed/30068361 http://dx.doi.org/10.1186/s13045-018-0644-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Liu, Ming Wang, Xu Wang, Lei Ma, Xiaodong Gong, Zhaojian Zhang, Shanshan Li, Yong Targeting the IDO1 pathway in cancer: from bench to bedside |
title | Targeting the IDO1 pathway in cancer: from bench to bedside |
title_full | Targeting the IDO1 pathway in cancer: from bench to bedside |
title_fullStr | Targeting the IDO1 pathway in cancer: from bench to bedside |
title_full_unstemmed | Targeting the IDO1 pathway in cancer: from bench to bedside |
title_short | Targeting the IDO1 pathway in cancer: from bench to bedside |
title_sort | targeting the ido1 pathway in cancer: from bench to bedside |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090955/ https://www.ncbi.nlm.nih.gov/pubmed/30068361 http://dx.doi.org/10.1186/s13045-018-0644-y |
work_keys_str_mv | AT liuming targetingtheido1pathwayincancerfrombenchtobedside AT wangxu targetingtheido1pathwayincancerfrombenchtobedside AT wanglei targetingtheido1pathwayincancerfrombenchtobedside AT maxiaodong targetingtheido1pathwayincancerfrombenchtobedside AT gongzhaojian targetingtheido1pathwayincancerfrombenchtobedside AT zhangshanshan targetingtheido1pathwayincancerfrombenchtobedside AT liyong targetingtheido1pathwayincancerfrombenchtobedside |